PQR309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy.
Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].
PMID: 29066507